Findings implicate mesenchymal stromal cells in the etiology of desmoid tumors, often associated with familial colon cancer syndromes, and they suggest novel strategies for systemic treatment of this disease.
Introduction
DTs, also known as aggressive fibromatosis, are mesenchymal tumors that occur sporadically or are associated with the heritable colorectal cancer syndrome, FAP. DTs exhibit locally destructive growth, with a dense infiltrative character that can produce disfigurement, functional deficits, and death (1) . Treatment often involves surgical excision, which is associated with high recurrence rates (2) . Although several studies reported successful regression of DTs with drug treatments and radiation therapy, effective systemic therapy remains elusive, in large part due to the limited understanding of its pathophysiology (3, 4, 5) .
A common feature of DTs is deregulated Wnt signaling via β-catenin-dependent activation of latent Tcf/Lef transcription factors. This pathway is critical in adult stem cell survival and self-renewal during wound healing (6) . DTs arising in patients with FAP show loss of APC tumor suppressor function (7, 8) . This leads to high intracellular β-catenin levels and is correlated with constitutive activation of Wnt signaling. In sporadic DTs, specific point mutations in the CTNNB1 gene that stabilize β-catenin protein achieve a similar result (9, 10) .
DTs can arise at sites of wound healing and demonstrate histologic features observed in dermal fibroproliferative disorders such as keloids and hypertrophic scarring (11, 12) . Normal wound healing is a tightly-regulated, self-limited process that produces rapid defect coverage to protect from further harm, then regenerates and remodels tissues at the injury site. In response to tissue stress or injury, mesenchymal cells from various sources are mobilized and recruited to wounds, where they engraft and promote healing (13, 14, 15) . These cells include hematopoietic stem cell (HSC)-derived monocyte precursors, which comprise a small fraction of circulating nucleated cells that also home to sites of tissue injury, engraft, and differentiate into CD34 4 differentiate into endothelial cells, fibroblasts, and myofibroblasts (16, 17, 18) . During the resolution phase of normal wound healing, recruited stem/progenitor cells undergo terminal differentiation or apoptosis. However, under conditions of chronic inflammation or tumor progression, these activated cells persist. For example, both MSCs and fibrocytes are found in keloids and hypertrophic scars (19, 20, 21) . Together, these multipotent cells cooperate synergistically to support angiogenesis, a hallmark of accelerated wound healing and fibrosis (22, 23, 24) . DTs exhibit features consistent with chronic wound healing, including increased angiogenesis and proliferation of fibroblast-like cells within a collagen matrix (25, 26) . DTs also express genes characteristic of myofibroblasts, further indicating that persistent recruitment of monocyte precursors and defective wound healing resolution play significant roles in DT neoplasia (27) .
Because of their association with wound healing, MSCs are implicated in DT formation.
Primary fibroblast cell lines have been derived from DTs; however, the growth conditions employed did not specifically select or expand MSCs (28, 29) . A recent report described the culture of putative MSCs from mouse DTs; however, these cells were not fully characterized (30, 31) . We hypothesized that DTs arise after MSCs acquire somatic mutations during the proliferative phase of wound healing in genes that increase the transcriptional potential of β-catenin-Tcf/Lef. To explore this idea, we examined the expression of stem cell markers in archived human DT specimens and established a DT-derived MSC line from a patient with FAP.
Our findings implicate MSCs in the etiology of DT and suggest novel targets for the systemic treatment of this disease. 
Materials & Methods

Human DT specimens and normal MSCs
Human DTs and matching adjacent fascia from a subset of the collection were obtained from surgical specimens excised from patients under an approved protocol by the Institutional Review Board at the Brigham and Women's Hospital (BWH). Tumors were fixed in 10% buffered formalin and embedded in paraffin for immunohistochemical analysis. Normal first passage adipose-derived MSCs were a generous gift from Dr. Martin L. Yarmush, Shriners
Hospital for Children, Boston, MA.
Immunohistochemistry
Serial sections (4 μm) of preserved DTs were de-paraffinized in a xylene and graded ethanol series. Antigen retrieval was performed in pH 6.0 citrate buffer (Millipore) by heating for 2 min in a decloaking chamber (Biocare Medical). Peroxidase activity was quenched using the Dual Endogenous Enzyme Block (Dako North America, Inc.) for 15 min at room temperature.
All primary antibody reactions were performed overnight at 4 o C. Antibodies are listed in Supplementary 
Cell culture & cell morphology analysis
To establish a DT cell line, a fresh tumor sample was immediately placed in Hepesbuffered saline supplemented with 15% FBS and antibiotics. In the laboratory, the tumor was 
Fluorescent Activated Cell Sorting analysis (FACS)
Cells were grown to near confluence and passaged, as described. After centrifugation, cell pellets were suspended in 4% formaldehyde and fixed for 10 min at 37°C, chilled on ice for Fig. 3D ) (27, 33) . Upon passage, the neuronal-like cells did not attach and were subsequently lost. While all subsequent characterizations were performed using DT-derived cells passaged less than 3 times, this cell line was maintained for at least 10 population doublings and appeared virtually immortal consistent with the self-renewal capability of stem cells.
Cultured DT cells were characterized by fluorescent immunohistochemistry to assess obligate MSC markers. The cell line co-expressed CD73, CD90, and CD105 (Endoglin) ( Fig. 2A and B). Appropriately, the transmembrane endothelial precursor marker, CD34, was not expressed in the DT-derived cells (Fig. 2C) . Additionally, the DT-derived cells were positively stained with antibodies for TGFβ1, 2, 3 and the active form of integrin β1, and displayed a prominent F-actin cytoskeleton upon staining with Alexa Fluor 568-labeled phalloidin (Supplementary Fig. 4A and B). To prove that these DT-derived cells were authentic MSCs, fluorescence-activated cell sorting (FACS) analysis of surface antigen profiles confirmed that ~90% of the population co-expressed MSC positive, but not negative markers (Fig. 2D ). Fluorescent immunohistochemistry assessed ALK1 and CD105 co-expression in DTs (Fig. 3B ).
CD34
Among many cells expressing CD105, a subset co-expressed ALK1. This result is consistent with the observation that fibrocytes express both CD34 and CD105, whereas MSCs lack CD34 expression (24) . As expected, neither CD105 nor ALK1 were expressed in the matched normal tissues from DT patients (Fig. 3B ).
Tri-lineage mesenchymal differentiation of DT-derived MSCs. In addition to FACS, multipotency must be demonstrated to confirm MSC status. The DT-derived cells were cultured for 5-6 weeks in differentiation medium, and then assayed for lineage-specific markers to confirm differentiation into chondrocytes, adipocytes, and osteocytes (Fig. 4) . Chondrocyte differentiation requires activity of the transcription factor, SOX9, and chondrocytes specifically express Connective Tissue Growth Factor (CTGF). Fluorescent immunohistochemistry showed that the DT-derived cells grown in chondrocyte differentiation medium co-expressed these markers, and confirmed nuclear localization of SOX9 (Fig. 4A) . Also, collagen proteoglycans present in the chondrocytes yielded the appropriate result when fixed DT-derived cells were subjected to Alcian Blue staining (Fig. 4B) . Osteocyte differentiation requires activity of the 
osteoblast-specific transcription factor RUNX2, and osteopontin (OPN) is a glycoprotein selectively secreted by osteocytes. Fluorescent immunohistochemistry showed that the DTderived cells grown in osteocyte differentiation medium expressed these markers with nuclear and cytoplasmic localization of RUNX2 (Fig. 4C) . In addition, a black precipitate characteristic of osteocyte mineralization was evident when these cells were subjected to von Kossa staining (Fig. 4D) . Adipocyte differentiation requires the activities of transcription regulators PPARγ and c/EBPα. Fluorescent immunohistochemistry showed that the DT-derived cells grown in adipocyte differentiation medium expressed these markers with nuclear localization of c/EPBα.
In addition, lipid droplets were present with Oil Red O staining ( Fig. 4E and F) . Taken together these data confirmed development of a multipotent MSC line from a human DT. (7). We confirmed that MSCs from both the original DT and the DTderived cell line were APC-deficient by performing fluorescent immunohistochemistry to detect the carboxy-vs. amino-terminus of APC. This assay showed that although the truncated APC product was present, MSCs in both the DT and the cell line lacked the APC carboxy terminus antigen, consistent with somatic LOH (Fig. 5A and B) . As a positive control, immunohistochemistry performed in parallel on first passage normal human adipose-derived MSCs confirmed the presence of both terminal ends of APC protein in these non-tumor cells (Fig. 5C ). Wnt signaling is activated in APC-deficient MSCs. APC loss leads to activation of Wnt signaling as demonstrated by the accumulation of nuclear β-catenin. Previously, we showed that abundant nuclear β-catenin was present in our archived DT library (36) . Nuclear β-catenin was also detected in DT-embedded MSCs, suggesting β-catenin stabilization (Fig. 6A) .
Immunostaining of DTs for the proliferation marker, Ki-67, showed that CD73 + MSCs were among the Ki-67 + population (Fig. 6B ).
Notch and Hedgehog pathways are activated in DT-derived MSCs. Activation of Notch and
Hedgehog signaling is implicated in the development of multiple cancers. To investigate the presence of Notch signaling in desmoid tumorigenesis, immunostaining of DTs showed that
MSCs expressed Notch-1 and its activation target, Hes-1 ( Fig. 7A and B) . Consistent with our findings in tumor specimens (Fig 1C and D) , we also found that the DT-derived cells expressed BMI-1, as well as its upstream Hedgehog activation target, Gli-1 ( Fig. 7C and D) . Notch signaling is presumed to play a positive role in regulating BMI-1 function since transcriptional repression of this target is relieved by γ-secretase inhibitors.
Discussion
In this study, we examined a tumor of mesenchymal origin to obtain insight into stromal cell interactions and desmoid tumorigenesis. We showed that both MSCs and HSCs are present in human DTs but not in matching adjacent normal tissues. We also produced a human DT- Importantly, their histological characteristics are indistinguishable from that of non-neoplastic lesions associated with abnormal wound healing, including hypertrophic scars or dermal keloids (19, 20, 21) . There are data suggesting that a wound healing response may induce DT formation (11, 12) . Indeed, clinicians treating patients with FAP have noted a tendency for surgery to increase DT growth, and it is not uncommon for sporadic DTs to present initially within surgical scars.
Tumorigenesis shares characteristics observed in wound healing. For instance, symmetrical stem cell division, a process yielding stem cell duplication rather than the stem cell and its committed progenitor, is a prominent feature of the proliferative phase of normal wound healing. Tumors are initiated by symmetrical stem cell division that entails fixation of a mutation inactivating a critical tumor suppressor gene, such as APC, or activating a specific oncogene, such as CTNNB1 (7, 8, 9, 10, 11, 12) . Tumor growth proceeds with continued self-renewal of the mutant stem cell and expansion of its progeny. Since DTs have a monoclonal origin (25, 26) , it is feasible that this initiating mutation occurs in a MSC recruited or activated in situ during the proliferative response to tissue stress or injury. In this scenario, the specific mutation allows stem cell growth without the normal instructive positional, spatial, and mechanical cues provided by the tissue microenvironment (37) . In particular, signaling via Wnt, Hedgehog, and Notch MSCs and HSCs cohabit the same niche in bone marrow, and a relationship of MSC-dependent support of HSCs is illustrated in co-culture studies, which show that expansion of HSCs in vitro is stimulated by the addition of MSCs (38, 39) . In a systemic response, MSCs and HSC-derived monocyte precursors are recruited to sites of tissue injury where both cell types proliferate. In a wound healing context, monocyte precursors differentiate into multipotent CD34 + fibrocytes, and, depending on the availability of certain cytokines, differentiate into endothelial cells or myofibroblasts (24) . Fibrocytes and myofibroblasts produce extracellular matrix components such as collagens and express matrix metalloproteinases, factors needed for tissue remodeling during wound healing (16, 17) . In circumstances where the proliferative phase of wound healing fails to terminate, myofibroblasts also express fibrogenic factors such as TGFβ and inflammatory mediators such as the prostaglandin, PGE 2 .
Here, we show that MSCs are present in DTs and may contribute to the etiology of these neoplasms. This latter claim is supported by the absence of APC +/+ protein in both the FAPassociated DT and its derived MSC line, indicating clonal expansion of a cell that acquired an APC loss of heterozygosity (Fig. 5) . Absent APC function, β-catenin is constitutively stabilized (Fig. 6 ). Although we previously noted abundant nuclear β-catenin in DTs and stromal cells, demonstrated that enforced Wnt signaling inhibits terminal differentiation of pre-adipocytes (MSC progenitors) and a similar conclusion was found in HSCs (41, 42) .
Our DT-derived MSC line also exhibited stem cell behavior (Fig. 2 and 4) . Therefore, notwithstanding APC loss or stabilized β-catenin protein, mutant MSCs associated with DT formation presumably remain non-autonomous for growth and maintenance, and require both supporting cells and a niche microenvironment. Similar to conditions in the bone marrow, we found that MSCs resided with CD34 + fibrocytes in DTs, suggesting that these latter cells may provide support for the MSC tumor cells (38) . MSCs and CD34+ fibrocytes also co-exist in keloids and hypertrophic scars, which DTs resemble histologically (19, 20, 21) . Our findings suggest that DT etiology resembles defective wound healing, and the presence of immature stromal progenitor cells in both dermal tumors and DTs may reflect Wnt signaling-dependent inhibition of differentiation (41, 42) . Furthermore, studies show that homing of HSC-derived progenitors to peripheral tissues under conditions of chronic inflammation causes fibrosis (43) .
It is therefore possible that the high levels of fibrosis and angiogenesis found in DTs derive from a tumor-associated inflammatory response, with persistent recruitment of CD34 + fibrocytes. sporadic DTs with stabilizing CTNNB1 mutations (7, 8, 9, 10, 11, 12) . Three Wnt target genes are relevant. Secreted Frizzled-related protein1 (sFRP1) is expressed in DTs and encodes a soluble Wnt receptor antagonist (27) . Although its loss allows constitutive Wnt signaling and drives cancer growth, SFRP1 gene expression, resulting in canonical Wnt pathway inhibition, increases non-cancerous stem cell self-renewal (44) . SFRP1 expression is downstream of Gli-1 activity, which we showed was expressed in DT-derived MSCs (Fig. 7D) . Importantly, SFRP1 expression regulates β-catenin activity in HSCs, and in DTs may promote the retention and maintenance of CD34 + fibrocytes (45) . We also showed that DTs contained CD73 + MSCs expressing CD44 (Fig. 1F ). CD44, a hyaluronic acid adhesion receptor, is up-regulated in APCdeficient cells and potently affects stem cell niche production and homing of HSC-derived progenitors (46) .
Our main goal is to identify aspects of DT biology that will define effective therapies for this challenging disease. Our results enable predictions about potential therapies for DTs that target either MSCs or CD34 + fibrocytes. We found that DT-derived MSCs expressed BMI-1 and the Hedghog signaling effector, Gli-1 ( Fig. 7C and D niche requirements of one or both. We showed that DT-derived APC-deficient MSCs were capable of terminal differentiation. Therefore, differentiation therapies such as PPARγ agonists or retinoids may be effective (48, 49) . Finally, our work shows that tumor MSC lines can be generated from human DTs, thereby providing a resource that can accelerate preclinical drug testing. 
